Indian Pharmaceutical Alliance says it is committed to help fight Covid-19

Towards this, the alliance and its members are working with the governments and other public agencies, pharma industry associations and all other key stakeholders, it said in a statement

coronavirus
A medical official measures the temperature of a passenger using an infrared thermometer, following the outbreak of coronavirus
Press Trust of India Mumbai
2 min read Last Updated : Mar 21 2020 | 4:26 PM IST

The national pharma lobby Indian Pharmaceutical Alliance (IPA) on Saturday said it will take every step to ensure that all coronavirus patients get timely access to medicines.

Towards this, the alliance and its members are working with the governments and other public agencies, pharma industry associations and all other key stakeholders, it said in a statement.

"We are closely monitoring orders and inventories. With an adequate stock of active pharma ingredients, finished product formulations and channel availability, we'd be able to sustain the supply of medicines for the coming months. We are not aware of any medicines shortage, to date," the alliance said.

The statement further said that the alliance is working closely with the International generic and biosimilar medicines association, the WHO, the Association of Affordable Medicines in the US, Medicines for Europe, and several other country associations to understand any potential impact on supply of medicines globally.

It further noted that the IPA is aligned to government initiatives of containment measures and social distancing while meeting supply commitments.

"We are committed to providing quality medicines to patients in the country as well as across the globe," it said.

The alliance also thanked the entire medical community for their selfless service to protect people from the pandemic.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusIndian Pharmaceuticals IndustryPharma sector

First Published: Mar 21 2020 | 4:04 PM IST

Next Story